Sage Therapeutics Inc. (SAGE)
NASDAQ (NMS) NASDAQ (NMS) Primary 
Sage Therapeutics, Inc. (SAGE) Investigation: Bronstein, Gewirtz & Grossman, LLC Encourages Investors to Seek Compensation for Alleged Wrongdoings
NEW YORK, NY / ACCESSWIRE / August 8, 2024 / Bronstein, Gewirtz & Grossman, LLC is investigating potential claims on behalf of purchasers of Sage Therapeutics, Inc. ("Sage" or "the Company") (NASDAQ:SAGE). Investors who purchased Sage securities are encouraged to obtain additional information and assist the investigation by visiting the firm's site: bgandg.com/SAGE.
Sage Therapeutics, Inc. (SAGE) Investigation: Bronstein, Gewirtz & Grossman, LLC Encourages Investors to Seek Compensation for Alleged Wrongdoings
NEW YORK, NY / ACCESSWIRE / August 7, 2024 / Bronstein, Gewirtz & Grossman, LLC is investigating potential claims on behalf of purchasers of Sage Therapeutics, Inc. ("Sage" or "the Company") (NASDAQ:SAGE). Investors who purchased Sage securities are encouraged to obtain additional information and assist the investigation by visiting the firm's site: bgandg.com/SAGE.
Sage Therapeutics, Inc. (SAGE) Investigation: Bronstein, Gewirtz & Grossman, LLC Encourages Investors to Seek Compensation for Alleged Wrongdoings
NEW YORK, NY / ACCESSWIRE / August 6, 2024 / Bronstein, Gewirtz & Grossman, LLC is investigating potential claims on behalf of purchasers of Sage Therapeutics, Inc. ("Sage" or "the Company") (NASDAQ:SAGE). Investors who purchased Sage securities are encouraged to obtain additional information and assist the investigation by visiting the firm's site: bgandg.com/SAGE.
Sage Therapeutics, Inc. (SAGE) Investigation: Bronstein, Gewirtz & Grossman, LLC Encourages Investors to Seek Compensation for Alleged Wrongdoings
NEW YORK, NY / ACCESSWIRE / August 5, 2024 / Bronstein, Gewirtz & Grossman, LLC is investigating potential claims on behalf of purchasers of Sage Therapeutics, Inc. ("Sage" or "the Company") (NASDAQ:SAGE). Investors who purchased Sage securities are encouraged to obtain additional information and assist the investigation by visiting the firm's site: bgandg.com/SAGE.
Sage Therapeutics, Inc. (SAGE) Investigation: Bronstein, Gewirtz & Grossman, LLC Encourages Investors to Seek Compensation for Alleged Wrongdoings
NEW YORK, NY / ACCESSWIRE / August 4, 2024 / Bronstein, Gewirtz & Grossman, LLC is investigating potential claims on behalf of purchasers of Sage Therapeutics, Inc. ("Sage" or "the Company") (NASDAQ:SAGE). Investors who purchased Sage securities are encouraged to obtain additional information and assist the investigation by visiting the firm's site: bgandg.com/SAGE.
Sage Therapeutics, Inc. (SAGE) Investigation: Bronstein, Gewirtz & Grossman, LLC Encourages Investors to Seek Compensation for Alleged Wrongdoings
NEW YORK, NY / ACCESSWIRE / August 2, 2024 / Bronstein, Gewirtz & Grossman, LLC is investigating potential claims on behalf of purchasers of Sage Therapeutics, Inc. ("Sage" or "the Company") (NASDAQ:SAGE). Investors who purchased Sage securities are encouraged to obtain additional information and assist the investigation by visiting the firm's site: bgandg.com/SAGE.
Sage Therapeutics (SAGE) Q2 Loss Wider Than Expected, Sales Rise
Sage Therapeutics (SAGE) incurs a wider-than-expected second-quarter 2024 loss. Collaboration revenues from Zurzuvae drive year-over-year revenue growth.
Sage Therapeutics, Inc. (SAGE) Investigation: Bronstein, Gewirtz & Grossman, LLC Encourages Investors to Seek Compensation for Alleged Wrongdoings
NEW YORK, NY / ACCESSWIRE / August 1, 2024 / Bronstein, Gewirtz & Grossman, LLC is investigating potential claims on behalf of purchasers of Sage Therapeutics, Inc. ("Sage" or "the Company") (NASDAQ:SAGE). Investors who purchased Sage securities are encouraged to obtain additional information and assist the investigation by visiting the firm's site: bgandg.com/SAGE.
Sage Therapeutics, Inc., (SAGE) Q2 2024 Earnings Call Transcript
Sage Therapeutics, Inc., (NASDAQ:SAGE ) Q2 2024 Earnings Conference Call July 31, 2024 4:30 PM ET Company Participants Ashley Kaplowitz - Vice President of Investor Relations and Capital Markets Barry Greene - Chief Executive Officer Chris Benecchi - Chief Business Officer Laura Gault - Chief Medical Officer Kimi Iguchi - Chief Financial Officer Mike Quirk - Chief Scientific Officer Conference Call Participants Salveen Richter - Goldman Sachs Anupam Rama - JPMorgan Yasmeen Rahimi - Piper Sandler Paul Matteis - Stifel Jay Olson - Oppenheimer. Ritu Baral - TD Cowen Brian Abrahams - RBC Capital Markets Laura Chico - Wedbush Securities David Hoang - Citigroup Tazeen Ahmad - Bank of America George Farmer - Scotiabank Vikram Purohit - Morgan Stanley Sumant Kulkarni - Canaccord Uy Ear - Muziho Douglas Tsao - H.C.
Sage Therapeutics, Inc. (SAGE) Reports Q2 Loss, Tops Revenue Estimates
Sage Therapeutics, Inc. (SAGE) came out with a quarterly loss of $1.70 per share versus the Zacks Consensus Estimate of a loss of $1.68. This compares to loss of $2.68 per share a year ago.
Sage Therapeutics, Inc. (SAGE) Investigation: Bronstein, Gewirtz & Grossman, LLC Encourages Investors to Seek Compensation for Alleged Wrongdoings
NEW YORK, NY / ACCESSWIRE / July 31, 2024 / Bronstein, Gewirtz & Grossman, LLC is investigating potential claims on behalf of purchasers of Sage Therapeutics, Inc. ("Sage" or "the Company") (NASDAQ:SAGE). Investors who purchased Sage securities are encouraged to obtain additional information and assist the investigation by visiting the firm's site: bgandg.com/SAGE.
Sage Therapeutics, Inc. (SAGE) Investigation: Bronstein, Gewirtz & Grossman, LLC Encourages Investors to Seek Compensation for Alleged Wrongdoings
Bronstein, Gewirtz & Grossman, LLC is investigating potential claims on behalf of purchasers of Sage Therapeutics, Inc. ("Sage" or "the Company") (NASDAQ:SAGE). Investors who purchased Sage securities are encouraged to obtain additional information and assist the investigation by visiting the firm's site: bgandg.com/SAGE.
